| 翻訳と辞書 |
| Matthias Tschöp ： ウィキペディア英語版 |
Matthias Tschöp
Matthias H. Tschöp (born April 7, 1967) is a German physician and scientist best known for novel therapeutic approaches to diabetes and obesity based on dissecting gut-brain communication. He is Alexander-von-Humboldt Professor〔(Award winners 2012: Prof. Dr. Matthias Tschöp. ) humboldt-professur.de. Retrieved on 2014-01-15.〕 and Chair of Metabolic Diseases at Technische Universität München. In addition, he serves as Research Director of the (Helmholtz Diabetes Center ) and Director of the (Institute for Diabetes and Obesity ) at Helmholtz Zentrum München. Matthias Tschöp also holds an Adjunct Professorship at Yale University and was elected into the German National Academy of Sciences Leopoldina in 2013.〔(Professor Dr. Matthias Tschöp elected member of the German National Academy of Sciences. ) Eurekalert.org. Retrieved on 2015-01-22.〕
== Career and research ==
Matthias Tschöp obtained an M.D. from the Ludwig Maximilian University of Munich (1993) where he worked as a clinician (1994-1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999-2002) and leading a research team at the (German Institute of Human Nutrition ) (Potsdam/Nuthetal 2002-2003). He served as a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003-2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009-2011).〔(American Society for Clinical Investigation (ASCI). ) the-asci.org. Retrieved on 2015-01-22.〕
Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in ''Nature'' is among today’s most frequently cited metabolism research papers.〔Tschöp M, Smiley D, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407(6806):908-13. PMC 11057670.〕 It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.
Together with his close collaborator Richard DiMarchi (Indiana University)〔Claiborn, Kathryn (August 1, 2011). (Masters of Metabolism: Matthias Tschöp and Richard DiMarchi. ) jci.org. Retrieved on 2015-01-22.〕 he discovered and validated novel gut hormone co-agonist peptides, which simultaneously target several neuroendocrine receptors and efficiently reduce body weight and improve glucose tolerance. Several of these compounds are now in clinical trials for the treatment of diabetes and obesity. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations.〔Gruber, Karl (March 2015). (Moving toward a more precise treatment of diabetes. ) thelancet.com. Retrieved on 2015-02-21.〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Matthias Tschöp」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|